Skip to main content
. 2022 Feb 15;12:2552. doi: 10.1038/s41598-022-06221-8

Figure 3.

Figure 3

Kaplan–Meier survival analysis of time to death and separately for improvement by ≥ 2 BOSCI points in 103 participants with moderate-severe COVID-19 randomized treatment with convalescent plasma versus placebo. *BOSCI: World Health Organization Blueprint Ordinal Scale for Clinical Improvement.